Abstract Objective: Nalmefene is a kappa-opioid receptor agonist/antagonist which is currently prescribed to reduce heavy drinking days. Adverse events (AEs) have previously been described in trials, but these trials excluded patients with psychiatric comorbidities. This is important as psychiatric disorders are frequently associated with alcohol use disorders; therefore, the specific AEs in this population should be investigated. Methods: Here, we describe the case of a patient with diagnosed alcohol use disorder and schizoaffective disorder who received treatment with nalmefene. Results: The patient showed decompensation of psychotic symptoms after two doses of medication, consisting of auditory hallucinations, delusions, and ideas of persecution. The symptoms improved two days after treatment discontinuation. Conclusions: This case indicates that the AEs of nalmefene should be specifically investigated in patients with psychiatric disorders.

中文翻译：

---

精神分裂症患者纳美芬治疗期间的精神失代偿：病例报告

摘要目的：纳美芬是一种κ-阿片受体激动剂/拮抗剂，目前用于减少大量饮酒天数。不良事件 (AE) 先前已在试验中描述过，但这些试验排除了患有精神疾病的患者。这很重要，因为精神障碍经常与酒精使用障碍有关；因此，应调查该人群中的特定 AE。方法：在这里，我们描述了一名接受纳美芬治疗的确诊酒精使用障碍和分裂情感障碍患者的案例。结果：患者在服用两剂药物后表现出精神症状代偿失调，包括幻听、妄想和被迫害的想法。停止治疗两天后症状有所改善。结论：